Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & PerspectivesShorts
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Laurence Albiges, MD, PhD

Advertisement

Articles by Laurence Albiges, MD, PhD

Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC

ByLaurence Albiges, MD, PhD
February 17th 2025

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Urology Times

    1

    Unmet needs and emerging solutions in MRI-guided prostate cancer care

    2

    HHS requests testosterone therapy label updates, citing new safety data

    3

    Microbial dysbiosis may predict response to CBM588 in mRCC

    4

    Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC

    5

    Retrospective study suggests differences in OAB therapy persistence among older adults

    • About Us
    • Advertise
    • Editorial
    • Contact Us
    • Job Board
    • Terms and Conditions
    • Privacy
    • Do not sell my Personnal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    • Contagion Live
    • CGT Live
    • Neurology Live
    • HCP Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    • Patient Care Online
    HCP Live Network
    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us